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previously unrecognized genotype-phenotype associations, GWAS have been predominantly conducted in populations of European ancestry and the data on non-European populations are scarce. Given the difference in allele and genotype frequencies and linkage disequilibrium (LD) patterns across the populations, the results obtained in white populations might not be directly applicable to the Japanese population. Population-specific GWAS might identify additional loci or genes influencing HDL-cholesterol levels, revealing pathways or underlying mechanisms for anti-atherogenic property of HDL. Thus, we conducted a genome-wide association analysis in a Japanese population in search of populationspecific genetic variations associated with HDL-cholesterol levels.
Methods

Study Population
Subjects who were between 40 and 75 years of age and not on medication for dyslipidemia were randomly selected from the Suita Study for genotyping by Illumina 550K (n=900; age range, 42-73 years). The study design of the Suita Study has been described previously. [22] [23] [24] [25] [26] [27] [28] [29] In brief, the sample consisted of 14,200 men and women (30 to 79 years of age at enrolment), stratified by gender and 10-year age groups (10 groups and 1,420 subjects in each group) who had been randomly selected from the municipal population registry. They were all invited by the use of a letter, to attend regular cycles of follow-up examinations (every 2 years).
To examine the association between genetic variations influencing HDL-cholesterol levels and the risk of myocardial infarction (MI), allele and genotype frequencies of HDL-associated SNPs (rs3764261 and rs467571) were compared between controls and MI cases. Subjects who were recruited into the Suita Study between April 2002 and February 2004 and were free from coronary artery disease served as controls (n=3,097). Patients with MI were randomly selected in-and outpatients with documented MI and were enrolled in the Division of Cardiology at the National Cardiovascular Center between May 2001 and April 2003 (n=589). Both controls and MI cases were of the same ethnicity (Japanese).
Only those who gave written informed consent were included in the study. The study protocol was approved by the Institutional Ethics Committee, and the Committee on Genetic Analysis and Gene Therapy of the National Cardiovascular Center.
Subjects were asked to estimate the amount and frequency of alcohol intake per week. Alcohol consumption was expressed as ethanol (g) per day.
Genotyping Assays
The genome-wide scan was carried out in 900 Japanese patients of both sexes using the Illumina Sentrix Human Hap550 BeadChip (Illumina Inc, San Diego, CA, USA). Genotyping was performed by Illumina Inc (San Diego, CA, USA). SNPs with a call rate of less than 90% and/or with a minor allele frequency (MAF) of less than 0.1 were excluded from the study, leaving 368,274 autosomal SNPs for the analysis. Deviation from the Hardy-Weinberg Equilibrium and the degree of LD were analyzed using HaploView 4.0 (http://www.broad.mit.edu/mpg/haploview/). 30 Twenty-two SNPs were genotyped in the remaining Suita sample (n=1,000-1,500) for validation of the associations observed in the initial subpopulation: 18 were selected from the top-ranked SNPs with a -log10P of >4.0 and 4 SNPs had a -log10P less than 4.0, ranging from 3.2 to 3.7. Genotyping was performed by using TaqMan allelic discrimination assays (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. Concordance rates between genotypes determined by Illumina and the TaqMan method were calculated by the re-genotyping of 213 SNPs present on the Illumina chip in 900 subjects by the TaqMan system, and were 99.3% on average.
Statistical Analysis
Data are expressed as mean ± standard deviation (SD). Continuous variables were tested for normality of distribution, and logarithmic transformation was applied for those with skewed distributions. Residuals, defined as the observed minus predicted values on the basis of confounding factors, were used for the genotype-phenotype association analysis by using one-way analysis of variance (ANOVA) tests. Covariates included in the model were derived from multiple logistic regression analysis and used to calculate a residual value for each variable. The level of genome-wide significance, expressed as a -log10P value, was adjusted for multiple testing by Bonferroni correction and set at a -log10P value of >6.87. Effect sizes were estimated for associations, meeting an arbitrary threshold of a -log10P value of >4.0 by linear regression analysis under an additive genetic model, with adjustment for sex, body mass index (BMI) and ethanol consumption. The least significant number (n) was estimated to obtain the sample size required to attain approximately 50% power for the given significance level (alpha), SD of the error (sigma), and the effect size (delta). Statistical analysis was performed using a JMP statistical package 7.0 (SAS Institute, Cary, NC. USA).
Results
Clinical characteristics of the Suita sample and a subgroup of subjects included for the initial GWAS are shown in Table 1 . As specified by the selection criteria, subjects included for the initial GWAS were younger and free from medication for dyslipidemia. Figure 1 summarizes the genome-wide association analyses for HDL-cholesterol adjusted for sex, BMI and ethanol consumption. Among the 368,274 SNPs examined, none of the markers achieved genome-wide significance after Bonferroni correction. There were 43 SNPs exceeding the arbitrary threshold of -log10P >4.0. The SNPs in LD as defined by the r 2 >0.6 were categorized into a single group, and only 1 representative SNP for each region is shown in Table 2 . The most significant SNP was rs3764261, which was located 5'upstream of CETP at chromosome 16q13, exhibiting a -log10P value of 6.17. Each additional copy of the minor A allele at rs3764261 was associated with an increase in HDL-cholesterol by 5.6 mg/dl (P=0.0002). This observation is in good agreement with the previous GWAS where genetic variants in (rs711752, rs1864163) or near the CETP gene (rs3764261, rs9989419, rs1800775, rs1566439, rs12596776) 14, [17] [18] [19] [20] [21] showed highly significant associations with HDL-cholesterol. The degree of LD (r 2 ) between SNPs across the CETP region and the strength of the association of each SNP with HDL-cholesterol adjusted for sex, BMI and ethanol consumption are plotted in Figure 2 . Although rs9989419 and rs1566439 have been reported to be strongly associated with HDL-cholesterol levels in previous studies, 17, 18, 20 we could not confirm the association in our initial screening of 900 subjects; -log10P for rs9989419 and rs1566439 was 1.18 and 0.07, respectively. The most significant SNP, rs3764261, was not correlated with rs9989419 or rs1566439 (r 2 <0.1). Despite the non-significant association, the effect size for rs9989419 (β, -1.13; P=0.37) suggests that the direction of the association is consistent with that found in previous studies, with the minor allele being associated with decreased HDL levels. It is possible that the significant association for rs9989419 was not detected because of the lower frequency of minor A allele in our Japanese sample (0.25) compared with those in white populations (0.35-0.40). 17, 18, 20 While the previously reported association of CETP with HDL-cholesterol was confirmed in our GWAS, we failed to replicate the association for recently identified HDL-associated genes such as MVK-MMAB and GALNT2. 18 Furthermore, well-established genes contributing to HDL levels including LPL, LIPC, LIPG, and ABCA1 were not listed among the top-ranked SNPs with a -log10P of >4.0 from our genome-wide scan ( Table 2 ). An examination of genetic variants within or near these genes (±100 kb) present on the Illumina 550K BeadChip did not reveal any significant association with HDL-cholesterol (Figuers 3A-F) .
To assess some of the observed associations in the initial genome-wide scan, we genotyped 22 SNPs in the remaining Suita sample (n=1,000-1,500). As seen in Table 3 , the initially observed associations became less significant by increasing the sample size, except for the genetic variants at the CETP locus (rs3764261 and rs1532624). Changes in HDL-cholesterol per additional copy of the minor allele at rs3764261 was estimated to be 6.2 mg/dl (P =3.4×10 -12 ). It is interesting to note that rs467571 located 5'upstream of FLJ45139 at 21q22 yielded an effect size of 7.9 (P =3.8×10 -5 ).
To determine whether the 2 SNPs (rs3764261 and rs467571), showing the minor allele being associated with higher levels of HDL-cholesterol, are protective against MI, genotype frequencies of these SNPs were compared between MI cases (n=589) and controls (n=3,097). The minor allele at rs3764261 was more prevalent in MI cases than in controls; 0.221 and 0.196 for MI cases and controls, respectively (nominal P=0.02). The association of rs3764261 with HDL-cholesterol levels was direction-consistent in the MI cases; sex-adjusted residuals for the minor homozygotes, heterozygotes and major homozyogotes were 4.36±8.11, 1.96±14.46 and -1.56±10.90, respectively (mean ± SD, P= 0.003). The effect size with adjustment for sex was estimated to be 2.79 (P=0.077). The non-significant difference in MAF between MI cases and controls was observed for rs467571 (0.106 vs 0.100, nominal P=0.56).
Discussion
From our GWA scan, the strongest association for HDLcholesterol was observed for rs3764261 located upstream of the CETP gene, which was further confirmed in a lager sample of the Suita study. This is one of the most replicated associations and our findings are in good agreement with the previous GWAS. 17, 18, 20 In the present analysis, none of the genetic variants exerted a greater influence on HDL levels than those at CETP. Similarly, the previous GWAS conducted in the general population sample of KORA (Cooperative Health Research in the Region of Augsburg) found CETP to be the only gene reaching the genome-wide significance at the initial screening level (n=1,643). 20 In contrast to the well-known anti-atherogenic property of HDL, the minor allele of rs3764261 associated with an increase in HDL-cholesterol was more frequent in MI cases than in controls. This apparently contradictory observation might be linked to the premature withdrawal of the clinical trial of the CETP inhibitor, torcetrapib, 31 suggesting that the increase in HDL-cholesterol as a result of CETP deficiency might not be necessarily associated with a lower risk of cardiovascular disease. In line with this view, a 4.94-year follow-up study involving more than 8,000 subjects reported an increased risk for coronary heart disease among subjects with the A allele of the promoter SNP of the CETP gene at -629, which was associated with higher HDL-cholesterol levels. 32 Although it has become clear that the anti-atherogenic property of HDL is not fully explained by the circulating level of HDL-cholesterol, 33 the importance of the heterogeneity of HDL in terms of its function and structure has not been emphasized in GWAS.
A previously unrecognized association with HDL-cholesterol was detected for rs467571 at chromosome 21q22. The increase in HDL-cholesterol per additional minor allele was estimated to be 7.9 (P =3.8×10 -5 ). Nearby genes of this intergenic variant include FLJ45139 and ETS2, neither of which has been previously implicated in lipid metabolism. It remains to be confirmed in a much larger study population whether the protective allele at rs467571 is associated with the reduced risk of MI.
Lack of association between the previously reported loci and HDL levels in our GWAS can be due to the insufficient statistical power of the initial screening. Using the effect size (2.4) and SD of the error (13.2) obtained from the association analysis of rs3764261, the least significant number to attain a significant result, corresponding to approximately 50% power, was estimated to be 972, 851, 709, and 567 at the significance level (-log10P) of 6.8, 6.0, 5.0 and 4.0, respectively. Although our sample size (n=900) is large enough to detect an association for the effect size similar to that for the strongly associated SNP at CETP, it is possible that our GWAS is inadequately powered such that the modest effect was not detected. Inability to replicate the associations of well-known candidate genes and HDL levels might be accounted for by incomplete or poor coverage in our GWAS. As discussed in the study examining the coverage of commercially available genotyping arrays, 34 it can be considered that the important causative or functional variants specific to a Japanese population are not well captured by the tag SNPs selected on the basis of HapMap data. In our replication attempts, increasing the sample size weakened the strength of the associations for most of the SNPs genotyped in the additional Suita sample. These SNPs are likely to have a lesser impact on HDL levels compared with those in CETP, and the proportion explained by these genetic variations is expected to be small. The use of a cutoff of MAF >0.1 can be another limitation of the current analysis. It is possible that multiple rare alleles with a much greater influence might be involved in determining HDL levels in the Japanese population. Sequencing of the coding regions of ABCA1, APOA1, and LCAT in individuals with HDL-cholesterol levels less than the 5 th percentile or greater than the 95 th percentile demonstrated the involvement of rare sequence variations in determining low HDL, 35 suggesting that the multiple rare allele hypothesis is a valid approach. GWAS can be useful for identifying genes existing in a disease pathway, but do not allow these multiple rare allele hypotheses to be tested. Thus, deep resequencing of the responsible genes identified through GWAS in both affected and unaffected subjects might be a promising strategy for future personalized prevention.
We have successfully replicated the association of CETP with HDL levels. A GWAS approach is so called "hypothesis-generating". 36 Assessment of the observed associations for the top-ranked SNPs in an independent population, coupled with functional studies examining the underlying mechanisms of the identified variants will be necessary before drawing a definite conclusion.
